Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

April 12, 2021

Study Completion Date

April 12, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

Rilzabrutinib

Rilzabrutinib tablet(s) administered orally

Trial Locations (1)

Investigational Site Number: 0001, Glendale

All Listed Sponsors

lead

Principia Biopharma, a Sanofi Company

INDUSTRY

NCT06444191 - Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter